Small molecule GLP-1 agonist shows superior tolerability
Yunovia (a subsidiary of Ildong Pharmaceutical Group) has received permission from the Ministry of Food and Drug Safety (MFDS) of Korea to begin a Phase I study for its small molecule glucagon-like peptide-1 (GLP-1) agonist for obesity and diabetes. The Phase I Multiple Ascending Dose (MAD)… Read More